ClinicalTrials.gg
CompletedNCT05033483Updated Apr 12, 2023

Do Iron Supplements Impact the Gut Microbiome of Women of Reproductive Age?

An interventional study of Ferrous Fumarate and Placebo in Iron-deficiency, Microbial Colonization and Anemia, sponsored by South Australian Health and Medical Research Institute. Completed at 1 site in Australia. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-12.

Sponsored by South Australian Health and Medical Research Institute · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing ferrous fumarate in Anemia, Iron-Deficiency — 2 open to participants now, 2 under way, none of them phase 3. ferrous fumarate · Anemia, Iron-Deficiency.

Enrollment
6th of 12
82 · median 74
Started
2021
the only one that year
No phase
6 of 12
2 open now
Registered
8th of 12
by date

Among the 12 studies testing ferrous fumarate in Anemia, Iron-Deficiency, this one is the 6th largest by enrollment, is the only one that started in 2021, is one of 6 with no phase, and was the 8th registered.

Anemia, Iron-Deficiency

602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

2 of the 12 studies testing ferrous fumarate in Anemia, Iron-Deficiency are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ferrous fumarate

ferrous fumarate: first FDA approval 1978 (NORMINEST FE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing ferrous fumarate in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

In this randomised controlled trial the investigators will determine whether taking iron supplements compared to placebo for 21 days alters the bacteria (microbiome) in the large intestine of non-pregnant female participants.

Read the detailed description

BACKGROUND: Many women take iron-containing supplements during pregnancy. Indeed, the World Health Organization recommends that all pregnant women in low-income countries take an iron supplement containing 60 mg/day of elemental iron to reduce iron deficiency and iron-deficiency anaemia. However, oral iron has poor bioavailability, less than 10% absorbed with the remainder passing into the large intestine unbound, potentially providing a competitive advantage to iron-dependent opportunistic pathogens in the large intestine.

In a large randomized control trial in children, iron supplementation was shown to promote the growth of pathogenic species (E. coli, S. aureus, and L. monocytogenes) and inhibited the growth of commensal species (Lactobacillus and Bifidobacterium). These pathogens are associated with enteric infections, while the commensals act on the host's immune system to prevent colonization and invasion by pathogens.

It is NOT known if iron supplementation during pregnancy impacts the maternal and infant microbiome and, by extension, how this affects the neonatal risk of infection and immune dysregulation. Vertical transmission of the maternal microbiome to the newborn is a major determinant of infant health. If maternal iron supplementation affects the infant's health, strategies would be required to mitigate this risk.

The investigators require preliminary data to show how oral iron supplementation alters the intestinal microbiome in women. The Investigators will recruit non-pregnant female participants as there is no risk of vertical transmission to an infant in non-pregnant women. The investigators will conduct the study in Australia because there is not a natural abundance of pathogens that could potentially cause harm to the women. Nevertheless, the investigators would expect a shift in the microbiome from non-iron to iron, requiring bacterial species to return to baseline after women stop taking the iron.

HYPOTHESIS: Daily iron supplementation versus placebo for 21 days will alter the stool microbiome composition compared to placebo in non-pregnant female participants of reproductive age.

METHODS: 80 female participants (18-45 y) will be randomized to receive capsules containing iron (65.7 mg of elemental iron as ferrous fumarate) or placebo to take daily for 21 days. Stool samples will be collected at baseline, 21 days, and 42 days (washout).

03

Conditions studied

  • Iron-deficiency
  • Microbial Colonization
  • Anemia

Keywords

  • iron supplements
  • microbiome
  • women
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to give

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding.
  • Planning on becoming pregnant
  • Diagnosed with iron deficiency and/or anaemia in the previous three months
  • Taken antibiotics in the past three months
  • Taken iron containing supplements in the past three months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Iron Supplement

    65.7 mg of iron as ferrous fumarate

    Dietary Supplement: Ferrous Fumarate

  • Active comparator
    Placebo

    0 mg of iron

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementFerrous Fumarate

    Gelatin capsule containing 200 mg ferrous fumarate and microcrystalline cellulose

    Also known as: Iron Fumarate, ferro-tab

  • Dietary supplementPlacebo

    Gelatin capsule containing microcrystalline cellulose

    Also known as: Control

06

What researchers measure

Primary outcomes

  1. Weighted UniFrac dissimilarity score

    Measure of microbiota beta-diversity

    Time frame: 21 days

Secondary outcomes

  1. Bray-Curtis dissimilarity score

    Measure of microbiota beta-diversity

    Time frame: 21 days

  2. Shannon Wiener Diversity

    Microbiota alpha-diversity score with adjustment for baseline levels

    Time frame: 21 days

  3. Faith's phylogenetic diversity

    Microbiota alpha-diversity score with adjustment for baseline levels

    Time frame: 21 days

  4. Taxonomic richness

    Microbiota alpha-diversity score with adjustment for baseline levels

    Time frame: 21 days

  5. Relative abundance of core bacterial taxa

    Relative abundance of taxa present in \>40% of baseline samples, with adjustment for baseline levels

    Time frame: 21 days

Other outcomes

  1. Weighted UniFrac dissimilarity score

    Measure of microbiota beta-diversity

    Time frame: 42 days (washout)

  2. Shannon-Wiener diversity

    Microbiota alpha-diversity score with adjustment for baseline levels

    Time frame: 42 days (washout)

  3. Bray-Curtis dissimilarity score

    Measure of microbiota beta-diversity

    Time frame: 42 days (washout)

  4. Faith's phylogenetic diversity

    Microbiota alpha-diversity score with adjustment for baseline levels

    Time frame: 42 days (washout)

  5. Taxonomic richness

    Microbiota alpha-diversity score with adjustment for baseline levels

    Time frame: 42 days (washout)

  6. Relative abundance of core bacterial taxa

    Relative abundance of taxa present in \>40% of baseline samples, with adjustment for baseline levels

    Time frame: 42 days (washout)

07

Study locations

1 site
  • SAHMRI
    Adelaide, South Australia 5000, Australia
08

References and documents

Individual participant data

Plan to share: Yes — Outlined below

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Following final data analysis and primary publication

Access criteria: Access to study data may be granted, upon review and approval of the Institutional Review Board, investigators, in accordance with South Australian Health and Medical Research Institute Women and Kids 'Guidelines and Agreement for the use of materials in an ancillary study associated with original clinical trials or cohort studies.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Nov 2021, 2 months.

Of 133 non-industry interventional studies with no phase under Anemia, Iron-Deficiency, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's 2 months is below that.

Counting every sponsor, half of 142 studies reached it within 11 months; a quarter within 3 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2021
First posted
Sep 2, 2021
StartActual
Aug 31, 2021
Primary completionActual
Nov 6, 2021
CompletionActual
Jan 1, 2022
Last update
Apr 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05033483
Lead sponsor
South Australian Health and Medical Research Institute
Collaborators
Flinders University
Responsible party
Sponsor
First posted
Sep 2, 2021
Start date
Aug 31, 2021
Primary completion
Nov 6, 2021
Completion
Jan 1, 2022
Last update
Apr 12, 2023

Study contacts

Steven Taylor, PhD
principal investigator · South Australian Health and Medical Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferrous fumarate

Start the discussion